AZD-4547featured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:204550
CAS#:1035270-39-3
Description:AZD4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.
Price and Availability
AZD-4547, purity > 98%, is in stock. The same day shipping out after order is received.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 204550Name: AZD-4547CAS#: 1035270-39-3Chemical Formula: C26H33N5O3Exact Mass: 463.25834Molecular Weight: 463.57192Elemental Analysis:C, 67.36; H, 7.18; N, 15.11; O, 10.35
Related CAS #:1035270-39-31394854-62-6
Synonym:AZD4547; AZD-4547; AZD 4547.
IUPAC/Chemical Name:N-(5-(3,5-dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3S,5R)-3,5-dimethylpiperazin-1-yl)benzamide
InChi Key:VRQMAABPASPXMW-HDICACEKSA-N
InChi Code:InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+
SMILES Code:O=C(NC1=NNC(CCC2=CC(OC)=CC(OC)=C2)=C1)C3=CC=C(N4C[C@H](C)N[C@H](C)C4)C=C3
Technical Data
Additional Information
Related CAS#Sci-Finder listed CAS#1394854-62-6for AZD-4547ChemIDplus listed CAS#1035270-39-3 for AZD-4547, see website: https://chem.nlm.nih.gov/chemidplus/rn/1035270-39-3 According to Sci-Finder, Chemical name for CAS#1394854-62-6:N-[3-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-5-yl]-4-(3,5-dimethyl-1-piperazinyl)benzamideChemical name for CAS#1035270-39-3:rel-N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]benzamide
References
1: Ramsey MR, Wilson C, Ory B, Rothenberg SM, FaquinW, Mills AA, Ellisen LW. FGFR2 signaling underlies p63 oncogenicfunction in squamous cell carcinoma. J Clin Invest. 2013 Aug1;123(8):3525-38. doi: 10.1172/JCI68899. Epub 2013 Jul 8. PubMed PMID:23867503; PubMed Central PMCID: PMC3726171.
2: Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL. AutocrineIGF-I/insulin receptor axis compensates for inhibition of AKT inER-positive breast cancer cells with resistance to estrogen deprivation.Breast Cancer Res. 2013 Jul 11;15(4):R55. [Epub ahead of print] PubMedPMID: 23844554.
3: Katoh M, Nakagama H. FGF Receptors: Cancer Biology and Therapeutics.Med Res Rev. 2013 May 21. doi: 10.1002/med.21288. [Epub ahead of print]PubMed PMID: 23696246.
4: Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA,Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE. A mechanism ofresistance to gefitinib mediated by cellular reprogramming and theacquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013Mar 25;2:e39. doi: 10.1038/oncsis.2013.4. PubMed PMID: 23552882; PubMedCentral PMCID: PMC3641357.
5: Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K,Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E,Zhang X, Ji Q. FGFR2 gene amplification in gastric cancer predictssensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res.2013 May 1;19(9):2572-83. doi: 10.1158/1078-0432.CCR-12-3898. Epub 2013Mar 14. PubMed PMID: 23493349.
6: Zhao R, Xie X, Shen GX. Effects of glycated low-density lipoproteinon cell viability, proliferation, and growth factors of mouse embryofibroblasts. Can J Physiol Pharmacol. 2013 Jan;91(1):64-70. doi:10.1139/cjpp-2012-0234. Epub 2013 Jan 21. PubMed PMID: 23369077.
7: Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y,Liu K, Dong Z, Zhu G, Qian Z, Tang L, Schöttle J, Zhan P, Ji Q, KilgourE, Smith PD, Brooks AN, Thomas RK, Gavine PR. Translating thetherapeutic potential of AZD4547 in FGFR1-amplified non-small cell lungcancer through the use of patient-derived tumor xenograft models. ClinCancer Res. 2012 Dec 15;18(24):6658-67. doi:10.1158/1078-0432.CCR-12-2694. Epub 2012 Oct 18. Erratum in: Clin CancerRes. 2013 Jul 1;19(13):3714. Schöttle, Jakob [added]. PubMed PMID:23082000.
8: Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L,Hampson M, Gavine PR, Cook SJ. Tumour cell responses to new fibroblastgrowth factor receptor tyrosine kinase inhibitors and identification ofa gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.Oncogene. 2013 Jun 20;32(25):3059-70. doi: 10.1038/onc.2012.319. Epub2012 Aug 6. PubMed PMID: 22869148.
9: Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM,Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, RiccardiR, Brat DJ, Guha A, Aldape K, Golfinos JG, Zagzag D, Mikkelsen T,Finocchiaro G, Lasorella A, Rabadan R, Iavarone A. Transforming fusionsof FGFR and TACC genes in human glioblastoma. Science. 2012 Sep7;337(6099):1231-5. doi: 10.1126/science.1220834. Epub 2012 Jul 26.PubMed PMID: 22837387; PubMed Central PMCID: PMC3677224.
10: Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S,Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T.AZD4547: an orally bioavailable, potent, and selective inhibitor of thefibroblast growth factor receptor tyrosine kinase family. Cancer Res.2012 Apr 15;72(8):2045-56. doi: 10.1158/0008-5472.CAN-11-3034. Epub 2012Feb 27. PubMed PMID: 22369928.
MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(ResearchTrianglePark,简称RTP),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中 文美帝药库医药科技公司创立于2008年总部位于美国东海岸
MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务。 MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务和分子有竞争力的价格。MedKoo是您可靠的合作伙伴采购药物发现和药物分子。 MedKoo是世界的抗癌化学试剂和激酶抑制剂供应商之一。我们制造,销售和分销用于肿瘤学研究的高质量抗癌小分子试剂。我们的使命是建立世界上全面的抗癌小分子集合。我们还为制药行业,医学研究组织和学术机构提供高质量的研究服务。我们致力于以具有竞争力的价格提供服务和分子。MedKoo是您可靠的药物发现和药物分子采购合作伙伴。 CRISPR-Cas9是近年兴起的用于靶向基因组特定位置,进行DNA修饰的重要工具。研究发现CRISPR是细菌为了应对病毒的攻击而演化而来的获得性免疫防御机制。具体来说,在CRISPR和Cas9的作用下,经由小RNA分子的引导,靶向并沉默入侵者遗传物质核酸的关键部分。在该系统中,crRNA(CRISPR-derivedRNA)与tracrRNA(trans-activatingRNA)结合形成的复合物能特异性识别靶基因序列,并引导Cas9核酸内切酶在靶定位点剪切双链DNA,随后,细胞的非同源末端连接修复机制(NHEJ)重新连接断裂处的基因组DNA,并引入插入或缺失突变。另外也可以提供一个外源双链供体DNA(Donor)通过同源重组(HR)整合进断裂处的基因组,从而达到对基因组DNA进行修饰的目的。
目前,CRISPR-Cas9系统的高效基因组编辑功能已被应用于多种生物,包括小鼠、大鼠、斑马鱼、秀丽隐杆线虫,也包含多种细菌和植物,甚至在人体上也有应用。
ebiomall.com